Compare Albemarle Corp. (ALB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs IDEXX Laboratories, Inc. — how do they compare? Albemarle Corp. trades at $127.92 (market cap $15.22B), while IDEXX Laboratories, Inc. trades at $557.94 (market cap $44.98B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3× Albemarle Corp.'s market cap, and Albemarle Corp. pays a 1.26% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ALB | IDXX | |
|---|---|---|
Market Cap | $15.22B | $44.98B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $766.68 |
52-Week Low | $67.30 | $514.61 |
Enterprise Value | $18.24B | $45.89B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
IDXX trades at $570.25, up 2.23% today, with strong technical momentum as it approaches resistance near $572. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics. Analyst sentiment is bullish with a $645 consensus target, though elevated valuations pose a risk.
Outlook remains positive given consistent earnings beats and strategic AI integration, but high P/E of 41.57 suggests limited margin for error. Key risks include competitive pressures and reliance on pet healthcare spending cycles. Institutional ownership trends and upcoming Q2 earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
